Brief: Chimeric Therapeutics Says Expanded Its License Agreement With University Of Pennsylvania
29/06/2022 02:32
June 29 (Reuters) - Chimeric Therapeutics Ltd CHM.AX :
* EXPANDED ITS LICENSE AGREEMENT WITH UNIVERSITY OF
PENNSYLVANIA
FOR CDH17 CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES
Source text for Eikon: ID:nASX2vfsNX
Further company coverage: CHM.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial